CR20210251A - Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer - Google Patents
Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncerInfo
- Publication number
- CR20210251A CR20210251A CR20210251A CR20210251A CR20210251A CR 20210251 A CR20210251 A CR 20210251A CR 20210251 A CR20210251 A CR 20210251A CR 20210251 A CR20210251 A CR 20210251A CR 20210251 A CR20210251 A CR 20210251A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pyridin
- pyrrolo
- dihydro
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos de la Fórmula general (I); y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R1a, R2, R3, R4, y (R5)a son como se definen en la presente, a composiciones farmacéuticas que comprenden dichos compuestos y sales de estos aceptables desde el punto de vista farmacéutico, y a métodos de uso de dichos compuestos, sales de estos aceptables desde el punto de vista farmacéutico y composiciones para el tratamiento del crecimiento anormal de células, que incluye cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767602P | 2018-11-15 | 2018-11-15 | |
| US201962909970P | 2019-10-03 | 2019-10-03 | |
| PCT/IB2019/059702 WO2020100027A1 (en) | 2018-11-15 | 2019-11-12 | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210251A true CR20210251A (es) | 2021-07-14 |
Family
ID=68771726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210251A CR20210251A (es) | 2018-11-15 | 2019-11-12 | Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US11142525B2 (es) |
| EP (1) | EP3880676B1 (es) |
| JP (1) | JP7118267B2 (es) |
| KR (1) | KR20210090675A (es) |
| CN (1) | CN113316576A (es) |
| AU (1) | AU2019378184B2 (es) |
| BR (1) | BR112021008991A2 (es) |
| CA (1) | CA3061392A1 (es) |
| CL (1) | CL2021001190A1 (es) |
| CO (1) | CO2021006114A2 (es) |
| CR (1) | CR20210251A (es) |
| CU (1) | CU20210035A7 (es) |
| DK (1) | DK3880676T3 (es) |
| DO (1) | DOP2021000088A (es) |
| EC (1) | ECSP21034668A (es) |
| ES (1) | ES2958948T3 (es) |
| FI (1) | FI3880676T3 (es) |
| GE (1) | GEP20227434B (es) |
| HR (1) | HRP20231089T1 (es) |
| HU (1) | HUE063367T2 (es) |
| IL (1) | IL283149A (es) |
| LT (1) | LT3880676T (es) |
| MD (1) | MD3880676T2 (es) |
| MX (1) | MX2021005754A (es) |
| PE (1) | PE20211868A1 (es) |
| PH (1) | PH12021551117A1 (es) |
| PL (1) | PL3880676T3 (es) |
| PT (1) | PT3880676T (es) |
| RS (1) | RS64655B1 (es) |
| SG (1) | SG11202104394XA (es) |
| SI (1) | SI3880676T1 (es) |
| TW (1) | TWI718758B (es) |
| UA (1) | UA127426C2 (es) |
| UY (1) | UY38471A (es) |
| WO (1) | WO2020100027A1 (es) |
| ZA (1) | ZA202103099B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102650496B1 (ko) | 2018-10-31 | 2024-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN115698004A (zh) * | 2020-05-01 | 2023-02-03 | 辉瑞公司 | 作为hpk1抑制剂的氮杂内酰胺化合物 |
| CN112409268A (zh) * | 2020-12-03 | 2021-02-26 | 西南交通大学 | 靶向Fam20C抑制剂的制备及其抗三阴性乳腺癌作用 |
| WO2022258044A1 (zh) * | 2021-06-11 | 2022-12-15 | 杭州中美华东制药有限公司 | 吡咯并吡啶酮类化合物及其制备方法和用途 |
| CN117693503A (zh) | 2021-07-20 | 2024-03-12 | 阿斯利康(瑞典)有限公司 | 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺 |
| WO2023023942A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same |
| WO2023030478A1 (zh) * | 2021-09-03 | 2023-03-09 | 浙江海正药业股份有限公司 | 吡啶并内酰胺类衍生物及其制备方法和用途 |
| WO2023057883A1 (en) * | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Crystalline form of azalactam compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5243049A (en) * | 1992-01-22 | 1993-09-07 | Neurogen Corporation | Certain pyrroloquinolinones: a new class of GABA brain receptor ligands |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| AR067585A1 (es) * | 2007-07-19 | 2009-10-14 | Schering Corp | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa |
| US10800773B2 (en) | 2016-09-12 | 2020-10-13 | Integral Health, Inc. | Monocyclic compounds useful as GPR120 modulators |
| CN110402248B (zh) | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| CN109265443B (zh) | 2017-07-18 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
| WO2019148005A1 (en) | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
-
2019
- 2019-11-11 US US16/679,820 patent/US11142525B2/en active Active
- 2019-11-12 PL PL19813943.8T patent/PL3880676T3/pl unknown
- 2019-11-12 PT PT198139438T patent/PT3880676T/pt unknown
- 2019-11-12 SI SI201930620T patent/SI3880676T1/sl unknown
- 2019-11-12 MD MDE20210902T patent/MD3880676T2/ro unknown
- 2019-11-12 KR KR1020217017777A patent/KR20210090675A/ko active IP Right Grant
- 2019-11-12 HR HRP20231089TT patent/HRP20231089T1/hr unknown
- 2019-11-12 PE PE2021000685A patent/PE20211868A1/es unknown
- 2019-11-12 SG SG11202104394XA patent/SG11202104394XA/en unknown
- 2019-11-12 WO PCT/IB2019/059702 patent/WO2020100027A1/en active Application Filing
- 2019-11-12 ES ES19813943T patent/ES2958948T3/es active Active
- 2019-11-12 EP EP19813943.8A patent/EP3880676B1/en active Active
- 2019-11-12 GE GEAP201915630A patent/GEP20227434B/en unknown
- 2019-11-12 HU HUE19813943A patent/HUE063367T2/hu unknown
- 2019-11-12 LT LTEPPCT/IB2019/059702T patent/LT3880676T/lt unknown
- 2019-11-12 BR BR112021008991-8A patent/BR112021008991A2/pt unknown
- 2019-11-12 CN CN201980089161.3A patent/CN113316576A/zh active Pending
- 2019-11-12 CA CA3061392A patent/CA3061392A1/en active Pending
- 2019-11-12 RS RS20230847A patent/RS64655B1/sr unknown
- 2019-11-12 FI FIEP19813943.8T patent/FI3880676T3/fi active
- 2019-11-12 CU CU2021000035A patent/CU20210035A7/es unknown
- 2019-11-12 AU AU2019378184A patent/AU2019378184B2/en active Active
- 2019-11-12 CR CR20210251A patent/CR20210251A/es unknown
- 2019-11-12 JP JP2021525702A patent/JP7118267B2/ja active Active
- 2019-11-12 MX MX2021005754A patent/MX2021005754A/es unknown
- 2019-11-12 DK DK19813943.8T patent/DK3880676T3/da active
- 2019-11-12 UA UAA202102538A patent/UA127426C2/uk unknown
- 2019-11-14 TW TW108141429A patent/TWI718758B/zh active
- 2019-11-14 UY UY0001038471A patent/UY38471A/es unknown
-
2021
- 2021-05-06 CL CL2021001190A patent/CL2021001190A1/es unknown
- 2021-05-07 DO DO2021000088A patent/DOP2021000088A/es unknown
- 2021-05-07 ZA ZA2021/03099A patent/ZA202103099B/en unknown
- 2021-05-11 CO CONC2021/0006114A patent/CO2021006114A2/es unknown
- 2021-05-12 IL IL283149A patent/IL283149A/en unknown
- 2021-05-14 EC ECSENADI202134668A patent/ECSP21034668A/es unknown
- 2021-05-14 PH PH12021551117A patent/PH12021551117A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551117A1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| US11958833B2 (en) | Compounds | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| CA2687265A1 (en) | P70 s6 kinase inhibitors | |
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| NZ600229A (en) | Triazolopyridines | |
| PE20141351A1 (es) | Triazolopiridinas | |
| WO2006067614A3 (en) | Heteroaromatic derivatives useful as anticancer agents | |
| NO20064046L (no) | Pyrazolpyrimidinderivater som syklinavhengige kinaseinhibitorer | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| US20170267696A1 (en) | Certain protein kinase inhibitors | |
| ZA202205900B (en) | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| US9867826B2 (en) | Heterocycles as modulators of kinase activity | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| MX2023003631A (es) | Indazoles a manera de inhibidores de cinasa 1 progenitora hematopoyetica (hpk1) y metodos de uso de los mismos. | |
| WO2006129168A3 (en) | Bicyclic derivatives for the treatment of abnormal cell growth | |
| MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. | |
| MX2021009173A (es) | El monohidrato de clorhidrato de rogaratinib y estados solidos del mismo. | |
| US10800785B2 (en) | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | |
| EA202191055A1 (ru) | ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ПИРРОЛО[3,4-с]ПИРИДИН-1-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ НРК1 ДЛЯ ЛЕЧЕНИЯ РАКА | |
| MX2017011423A (es) | Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. | |
| WO2022061155A9 (en) | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 |